CN1192680A - 抑制接合蛋白/酪氨酸激酶相互作用的方法与组合物 - Google Patents

抑制接合蛋白/酪氨酸激酶相互作用的方法与组合物 Download PDF

Info

Publication number
CN1192680A
CN1192680A CN96196106A CN96196106A CN1192680A CN 1192680 A CN1192680 A CN 1192680A CN 96196106 A CN96196106 A CN 96196106A CN 96196106 A CN96196106 A CN 96196106A CN 1192680 A CN1192680 A CN 1192680A
Authority
CN
China
Prior art keywords
benzoquinone
indol
dihydroxy
methylbut
represent hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN96196106A
Other languages
English (en)
Chinese (zh)
Inventor
邓炳初
G·麦马雄
G·D·哈里斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sugen LLC
Original Assignee
Sugen LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sugen LLC filed Critical Sugen LLC
Publication of CN1192680A publication Critical patent/CN1192680A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN96196106A 1995-06-07 1996-06-05 抑制接合蛋白/酪氨酸激酶相互作用的方法与组合物 Pending CN1192680A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47613695A 1995-06-07 1995-06-07
US08/476,136 1995-06-07

Publications (1)

Publication Number Publication Date
CN1192680A true CN1192680A (zh) 1998-09-09

Family

ID=23890650

Family Applications (1)

Application Number Title Priority Date Filing Date
CN96196106A Pending CN1192680A (zh) 1995-06-07 1996-06-05 抑制接合蛋白/酪氨酸激酶相互作用的方法与组合物

Country Status (11)

Country Link
US (4) US5780496A (enExample)
EP (1) EP0831809A4 (enExample)
JP (1) JPH11506770A (enExample)
KR (1) KR19990022369A (enExample)
CN (1) CN1192680A (enExample)
AR (1) AR003140A1 (enExample)
BR (1) BR9609353A (enExample)
CA (1) CA2224103A1 (enExample)
IL (1) IL122427A0 (enExample)
MX (1) MX9709442A (enExample)
WO (1) WO1996040115A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114630819A (zh) * 2019-11-19 2022-06-14 韩国化学研究院 用于预防或治疗癌症的苯甲酰胺衍生物、其制备方法以及包含其作为活性成分的药物组合物

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593852A (en) * 1993-12-02 1997-01-14 Heller; Adam Subcutaneous glucose electrode
CA2050057A1 (en) 1991-03-04 1992-09-05 Adam Heller Interferant eliminating biosensors
US5786488A (en) 1996-11-13 1998-07-28 Sugen, Inc. Synthetic methods for the preparation of indolyquinones
US6376529B1 (en) 1995-06-07 2002-04-23 Peng Cho Tang Mono- and bis-indolylquinones and prophylactic and therapeutic uses thereof
EP0944720A1 (en) 1996-12-03 1999-09-29 Sugen, Inc. Adaptor protein frs2 and related products and methods
US6051597A (en) * 1997-06-13 2000-04-18 Merck & Co., Inc. Indolylquinones as antidiabetic agents
CA2321307A1 (en) 1998-02-27 1999-09-02 Venkatachala L. Narayanan Disubstituted lavendustin a analogs and pharmaceutical compositions comprising the analogs
US6077849A (en) * 1998-04-02 2000-06-20 Merck & Co., Inc. Antidiabetic agents
US8465425B2 (en) 1998-04-30 2013-06-18 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8346337B2 (en) 1998-04-30 2013-01-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6949816B2 (en) * 2003-04-21 2005-09-27 Motorola, Inc. Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same
US20080076997A1 (en) * 1998-04-30 2008-03-27 Abbott Diabetes Care, Inc. Analyte monitoring device and methods of use
US6175752B1 (en) 1998-04-30 2001-01-16 Therasense, Inc. Analyte monitoring device and methods of use
US9066695B2 (en) 1998-04-30 2015-06-30 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8480580B2 (en) 1998-04-30 2013-07-09 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8974386B2 (en) 1998-04-30 2015-03-10 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8688188B2 (en) * 1998-04-30 2014-04-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6307090B1 (en) 1999-01-22 2001-10-23 The United States Of America As Represented By The Department Of Health And Human Services Acylated oligopeptide derivatives having cell signal inhibiting activity
WO2000056760A1 (en) * 1999-03-23 2000-09-28 The United States Of America, Represented By Secretary, Department Of Health And Human Services Phenylalanine derivatives
US7226991B1 (en) * 1999-03-23 2007-06-05 United States Of America, Represented By The Secretary, Department Of Health And Human Services Phenylalanine derivatives
WO2001028577A2 (en) 1999-10-22 2001-04-26 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Inhibition of cell motility and angiogenesis by inhibitors of the grb2 sh2-domain
US7871981B2 (en) * 1999-10-22 2011-01-18 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of cell motility, angiogenesis, and metastasis
US6165728A (en) * 1999-11-19 2000-12-26 Isis Pharmaceuticals Inc. Antisense modulation of NCK-2 expression
CA2419870A1 (en) * 2000-08-22 2002-02-28 Yang Gao Sh2 domain binding inhibitors
US7425537B2 (en) * 2000-08-22 2008-09-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services SH2 domain binding inhibitors
US6560471B1 (en) 2001-01-02 2003-05-06 Therasense, Inc. Analyte monitoring device and methods of use
US7151162B2 (en) * 2001-12-06 2006-12-19 The University Of Children's Hospital Of Both Cantons Of Basel Nuclear protein
US7057052B2 (en) 2002-09-26 2006-06-06 Duke University Heterocyclic quinones as pharmaceutical agents
EP1578262A4 (en) 2002-12-31 2007-12-05 Therasense Inc CONTINUOUS BLOOD SUGAR MONITORING SYSTEM AND USE METHOD
US20040138104A1 (en) * 2003-01-14 2004-07-15 The Government Of The United States Of America Represented By The Secretary, Peptides
US20050119163A1 (en) * 2003-09-18 2005-06-02 The Government Of The United States Of America, As Represented By The Secretary, SH2 domain binding inhibitors
US8600920B2 (en) * 2003-11-28 2013-12-03 World Assets Consulting Ag, Llc Affinity propagation in adaptive network-based systems
AR050253A1 (es) 2004-06-24 2006-10-11 Smithkline Beecham Corp Compuesto derivado de indazol carboxamida, composicion que lo comprende y su uso para la preparacion de un medicamento
JP2008532926A (ja) * 2004-12-06 2008-08-21 アバンテイス・フアルマ・エス・アー 置換インドール化合物、それを含有する組成物、この製造方法およびこの使用
FR2878849B1 (fr) * 2004-12-06 2008-09-12 Aventis Pharma Sa Indoles substitues, compositions les contenant, procede de fabrication et utilisation
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
AR065804A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
US8354539B2 (en) 2009-03-10 2013-01-15 Glaxo Group Limited Indole derivatives as IKK2 inhibitors
NZ601635A (en) * 2010-01-27 2013-06-28 Takeda Pharmaceutical Compounds for suppressing a peripheral nerve disorder induced by an anti-cancer agent
US9912758B2 (en) 2014-12-16 2018-03-06 Yahoo Holdings, Inc. Continuing an application session on a different device
CN120365272A (zh) 2018-10-05 2025-07-25 安娜普尔纳生物股份有限公司 用于治疗与apj受体活性有关的疾病的化合物和组合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3917820A (en) * 1969-05-29 1975-11-04 Canadian Patents Dev Antibiotic cochliodinol and production by chaetomium, cochliodes and chaetomium globsum
JPH0236591B2 (ja) * 1979-08-27 1990-08-17 Kyoto Pharma Ind Kinonjudotai
JPS6191167A (ja) * 1984-10-08 1986-05-09 Kyoto Yakuhin Kogyo Kk キノン誘導体
JPS6360966A (ja) * 1986-08-29 1988-03-17 Kyoto Yakuhin Kogyo Kk キノン誘導体
SE8903455D0 (sv) * 1989-10-19 1989-10-19 Joakim Nelson Dynamiska digitala foerbindelsenaet (dfn)
US5469431A (en) * 1993-07-12 1995-11-21 Philips Electronics North America Corp. Method of and apparatus for channel mapping with relative service identification
DE4329010A1 (de) * 1993-08-28 1995-03-02 Sel Alcatel Ag Funksystem
US6205143B1 (en) * 1996-03-14 2001-03-20 Telefonaktiebolaget L M Ericsson System supporting variable bandwidth asynchronous transfer mode network access for wireline and wireless communications
US5841777A (en) * 1996-08-30 1998-11-24 Hewlett-Packard Company System and method for accommodating ABR and CBR traffic on a shared communications channel
US6363058B1 (en) * 1997-09-24 2002-03-26 Telefonaktiebolaget L M Ericsson (Publ) Multi-service handling by a single mobile station
FI980293A7 (fi) * 1998-02-09 1999-08-10 Nokia Corp Multimedia- ja monipalvelupuhelut matkaviestinverkossa
CN1284243A (zh) * 1998-11-30 2001-02-14 诺基亚网络有限公司 空中接口容量调度方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114630819A (zh) * 2019-11-19 2022-06-14 韩国化学研究院 用于预防或治疗癌症的苯甲酰胺衍生物、其制备方法以及包含其作为活性成分的药物组合物
CN114630819B (zh) * 2019-11-19 2024-02-13 韩国化学研究院 用于预防或治疗癌症的苯甲酰胺衍生物、其制备方法以及包含其作为活性成分的药物组合物

Also Published As

Publication number Publication date
IL122427A0 (en) 1998-06-15
WO1996040115A1 (en) 1996-12-19
CA2224103A1 (en) 1996-12-19
AR003140A1 (es) 1998-07-08
US20020016353A1 (en) 2002-02-07
US6239161B1 (en) 2001-05-29
BR9609353A (pt) 1999-05-11
JPH11506770A (ja) 1999-06-15
EP0831809A1 (en) 1998-04-01
MX9709442A (es) 1998-02-28
KR19990022369A (ko) 1999-03-25
AU5979996A (en) 1996-12-30
EP0831809A4 (en) 2001-11-28
US5780496A (en) 1998-07-14
AU697120B2 (en) 1998-09-24
US6090838A (en) 2000-07-18

Similar Documents

Publication Publication Date Title
CN1192680A (zh) 抑制接合蛋白/酪氨酸激酶相互作用的方法与组合物
CN1167420C (zh) 用于调制丝氨酸/苏氨酸蛋白激酶功能的氮杂苯并咪唑类化合物
CN1067054C (zh) 1H-吲哚-3-乙醛酰胺sPLA2抑制剂
CN1174981C (zh) 咪唑并[1,2-a]吡啶和吡唑并[2,3-a]吡啶衍生物
CN1264824C (zh) 喹唑啉衍生物
CN1185229C (zh) 用作糖原合酶激酶－3β抑制剂的3－吲哚基－4－苯基－1H－吡咯－2,5－二酮衍生物
CN1111454A (zh) 亚芳基和杂亚芳基羟吲哚衍生物及其制备方法
CN101052394A (zh) 使用二氢吲哚酮化合物治疗急性骨髓性白血病
CN1290844C (zh) 用作蛋白激酶抑制剂的二氢吲哚酮衍生物
CN1274284A (zh) 用5－氮杂喹喔啉类化合物调节丝氨酸/苏氨酸蛋白激酶功能的方法
CN1675214A (zh) 具有抗增殖活性的嘧啶并化合物
CN1179960C (zh) 吲哚衍生物和其在治疗骨质疏松中的应用以及其它应用
CN1278794A (zh) 用作蛋白酪氨酸激酶和蛋白丝氨酸/苏氨酸激酶抑制剂的取代的2－羟基吲哚衍生物
CN1543346A (zh) 新化合物
CN1433312A (zh) 作为治疗剂的巴比妥酸类似物
CN1214339A (zh) 吡唑衍生物、其制备方法和在药物中的应用
CN1208413A (zh) 促性腺激素释放激素拮抗剂
CN1072219C (zh) 二氮杂䓬酮、其生产和用途
CN1678306A (zh) 在炎性、变应性和增生性疾病中用作糖皮质激素模拟物的3－(磺酰氨基乙基)－吲哚衍生物
CN1040193A (zh) 烷氧基-4(1h)-吡啶酮衍生物的制备
CN1503794A (zh) 作为抗癌剂的细胞周期蛋白依赖性激酶抑制剂
CN87103504A (zh) 杂环羧酰胺
CN1835929A (zh) 作为pde9a抑制剂的6－芳氨基－5－氰基－4－嘧啶酮类化合物
CN1125942A (zh) N-取代的β-芳基-和β-杂芳基-α-氰基丙烯酰胺衍生物及其制备
CN1244577C (zh) 4－苯基－1－哌嗪基、－哌啶基和－四氢吡啶基衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C01 Deemed withdrawal of patent application (patent law 1993)
WD01 Invention patent application deemed withdrawn after publication